Klaria Pharma Holding AB (6FN) Stock Statistics & Valuation Metrics

Klaria Pharma Holding AB has a market cap or net worth of €18.52M. The enterprise value is €276.68M.

Klaria Pharma Holding AB has 245,976,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Klaria Pharma Holding AB’s return on equity (ROE) is 10.02 and return on invested capital (ROIC) is 773.67%.

The current PE Ratio of Klaria Pharma Holding AB is ―. Klaria Pharma Holding AB’s PEG ratio is 0.07.

In the last 12 months, Klaria Pharma Holding AB had revenue of 9.00M and earned -38.90M in profits. Earnings per share was -0.21.

In the last 12 months, operating cash flow was -35.04M and capital expenditures 35.04M, giving a free cash flow of 0.00 billion.

Klaria Pharma Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―

Klaria Pharma Holding AB upcoming earnings date is May 8, 2026, TBA (Confirmed).

Klaria Pharma Holding AB as a current ratio of 0.05, with Debt / Equity ratio of 0.00%

In the past 12 months, Klaria Pharma Holding AB has paid 0.00 in taxes.

Klaria Pharma Holding AB EV to EBITDA ratio is -8.78, with an EV/FCF ratio of 0.00.

Klaria Pharma Holding AB has €342.00K in cash and marketable securities with €0.00 in debt, giving a net cash position of €342.00K billion.

Gross margin is 99.83%, with operating margin of -280.41%, and net profit margin of -432.22%.

The average price target for Klaria Pharma Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―